학술논문
AML-029 Quizartinib Prolonged Overall Survival (OS) vs Placebo Plus Intensive Induction and Consolidation Therapy Followed by Single-Agent Continuation in Patients Aged 18-75 Years With Newly Diagnosed FLT3–Internal Tandem Duplication Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML)
Document Type
Article
Author
Erba, Harry ; Montesinos, Pau ; Vrhovac, Radovan ; Patkowska, Elzbieta ; Kim, Hee-Je ; Zak, Pavel ; Wang, Po-Nan ; Mitov, Tsvetomir ; Hanyok, James ; Liu, Li ; Benzohra, Aziz ; Lesegretain, Arnaud ; Cortes, Jorge ; Perl, Alexander ; Sekeres, Mikkael ; Dombret, Hervé ; Amadori, Sergio ; Wang, Jianxiang ; Levis, Mark ; Schlenk, Richard
Source
In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S208-S209
Subject
Language
ISSN
2152-2650